Protalix BioTherapeutics, Inc. (PLX) Deep Dive Video
Summary
Protalix’s debt-free commercial platform and Elfabrio growth create asymmetric upside, but single-site Israeli manufacturing and PRX-115 clinical risk demand a speculative risk tolerance.
View PLX stock page · Read the PLX research report
Loading the video player…